The expression of genes encoding antioxidant enzymes in lung adenocarcinoma A549 cells exposed to cisplatin supplemented by polyunsaturated fatty acids

Advances in Clinical and Experimental Medicine

Volumn 19, Issue 5, 2010, Pages 585-591

  Zajdel, Alicja ^a   Wilczok, Adam ^a   Gruchlik, Arkadiusz ^a   Paduszyński, Piotr ^a   Dzierzewicz, Zofia ^a  

^a UNIVERSITY OF SILESIA   (Poland)

Author keywords

A549 cells; Antioxidant enzymes; Cisplatin; PUFAs

Indexed keywords

CISPLATIN; COPPER ZINC SUPEROXIDE DISMUTASE; DOCOSAHEXAENOIC ACID; ENZYME; GLUTATHIONE TRANSFERASE P1; ICOSAPENTAENOIC ACID; MANGANESE SUPEROXIDE DISMUTASE; MESSENGER RNA; PHOSPHOLIPID HYDROPEROXIDE GLUTATHIONE PEROXIDASE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CELL VIABILITY; CONCENTRATION RESPONSE; CYTOTOXICITY; DOWN REGULATION; DRUG POTENTIATION; DRUG SENSITIVITY; GENE EXPRESSION; HUMAN; HUMAN CELL; OXIDATION REDUCTION POTENTIAL; SENSITIZATION;

EID: 78650010950     PISSN: 1230025X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Siddik ZH: Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 2003, 22, 7265-7279.
2. Wang D, Lippard SJ: Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov 2005, 4, 307-320. (Pubitemid 41130944)
3. Ohmichi M, Hayakawa J, Tasaka K, Kurachi H, Murata Y: Mechanisms of platinum drug resistance. Trends Pharmacol Sci 2005, 26, 113-116.
4. Berndtsson M, Hagg M, Panaretakis T, Havelka AM, Shoshan MC, Linder S: Acute apoptosis by cisplatin requires induction of reactive oxygen species but is not associated with damage to nuclear DNA. Int J Cancer 2007, 120, 175-180.
5. Pelicano H, Carney D, Huang P: ROS stress in cancer cells and therapeutic implications. Drug Resist Updat 2004, 7, 97-110. (Pubitemid 38736063)
6. Cho JM, Manandhar S, Lee HR, Park HM, Kwak MK: Role of the Nrf2-antioxidant system in cytotoxicity mediated by anticancer cisplatin: implication to cancer cell resistance. Cancer Lett 2008, 260, 96-108.
7. Kakolyris S, Giatromanolaki A, Koukourakis M, Powis G, Souglakos J, Sivridis E, Georgoulias V, Gatter KC, Harris AL: Thioredoxin expression is associated with lymph node status and prognosis in early operable non-small cell lung cancer. Clin Cancer Res 2001, 7, 3087-3091.
8. Kinnula VL, Pääkkö P, Soini Y: Antioxidant enzymes and redox regulating thiol proteins in malignancies of human lung. FEBS Lett 2004, 569, 1-6.
9. Berquin IM, Edwards IJ, Chen YQ: Multi-targeted therapy of cancer by omega-3 fatty acids. Cancer Lett 2008, 269, 363-377.
10. Siddiqui RA, Harvey K, Stillwell W: Anticancer properties of oxidation products of docosahexaenoic acid. Chem Phys Lipids 2008, 153, 47-56.
11. Pardini RS: Nutritional intervention with omega-3 fatty acids enhances tumor response to anti-neoplastic agents. Chem Biol Interact 2006, 162, 89-105.
12. Ding WQ, Vaught JL, Yamauchi H, Lind SE: Differential sensitivity of cancer cells to docosahexaenoic acid-induced cytotoxicity: the potential importance of down-regulation of superoxide dismutase 1 expression. Mol Cancer Ther 2004, 3, 1109-1117.
13. Ding WQ, Lind SE: Phospholipid hydroperoxide glutathione peroxidase plays a role in protecting cancer cells from docosahexaenoic acid-induced cytotoxicity. Mol Cancer Ther 2007, 6, 1467-1474.
14. Vibet S, Goupille C, Bougnoux P, Steghens JP, Goré J, Mahéo K: Sensitization by docosahexaenoic acid (DHA) of breast cancer cells to anthracyclines through loss of glutathione peroxidase (GPx1) response. Free Radic Biol Med 2008, 44, 1483-1491.
15. Singh A, Misra V, Thimmulappa RK, Lee H, Ames S, Hoque MO, Herman JG, Baylin SB, Sidransky D, Gabrielson E, Brock MV, Biswal S: Dysfunctional KEAP1-NRF2 interaction in non-small-cell lung cancer. PLoS Med 2006, 3, e420.
16. Padmanabhan B, Tong KI, Ohta T, Nakamura Y, Scharlock M, Ohtsuji M, Kang MI, Kobayashi A, Yokoyama S, Yamamoto M: Structural basis for defects of Keapl activity provoked by its point mutations in lung cancer. Mol Cell 2006, 21, 689-700. (Pubitemid 43290735)
17. Ohta T, Iijima K, Miyamoto M, Nakahara I, Tanaka H, Ohtsuji M, Suzuki T, Kobayashi A, Yokota J, Sakiyama T, Shibata T, Yamamoto M, Hirohashi S: Loss of Keapl function activates Nrf2 and provides advantages for lung cancer cell growth. Cancer Res 2008, 68, 1303-1309.
18. Wang XJ, Sun Z, Villeneuve NF, Zhang S, Zhao F, Li Y, Chen W, Yi X, Zheng W, Wondrak GT, Wong PK, Zhang DD: Nrf2 enhances resistance of cancer cells to chemotherapeutic drugs, the dark side of Nrf2. Carcinogenesis 2008, 29, 1235-1243.
19. Kinnula VL, Crapo JD: Superoxide dismutases in malignant cells and human tumors. Free Radic Biol Med 2004, 36, 718-744. (Pubitemid 38264416)
20. Järvinen K, Pietarinen-Runtti P, Linnainmaa K, Raivio KO, Krejsa CM, Kavanagh T, Kinnula VL: Antioxidant defense mechanisms of human mesothelioma and lung adenocarcinoma cells. Am J Physiol Lung Cell Mol Physiol 2000, 278, L696-702.
21. Goto S, Kamada K, Soh Y, Ihara Y, Kondo T: Significance of nuclear glutathione S-transferase pi in resistance to anti-cancer drugs. Jpn J Cancer Res 2002, 93, 1047-1056. (Pubitemid 35154272)
22. Kriska T, Korytowski W, Girotti AW: Hyperresistance to photosensitized lipid peroxidation and apoptotic killing in 5-aminolevulinate-treated tumor cells overexpressing mitochondrial GPX4. Free Radic Biol Med 2002, 33, 1389-1402. (Pubitemid 35284922)
23. Miyamoto Y, Koh YH, Park YS, Fujiwara N, Sakiyama H, Misonou Y, Ookawara T, Suzuki K, Honke K, Taniguchi N: Oxidative stress caused by inactivation of glutathione peroxidase and adaptive responses. Biol Chem 2003, 384, 567-574. (Pubitemid 36609172)
24. Mahéo K, Vibet S, Steghens JP, Dartigeas C, Lehman M, Bougnoux P, Goré J: Differential sensitization of cancer cells to doxorubicin by DHA: a role for lipoperoxidation. Free Radic Biol Med 2005, 39, 742-751.
25. Timmer-Bosscha H, Hospers GA, Meijer C, Mulder NH, Muskiet FA, Martini IA, Uges DR, de Vries EG: Influence of docosahexaenoic acid on cisplatin resistance in a human small cell lung carcinoma cell line. J Natl Cancer Inst 1989, 81, 1069-1075.
26. Plumb JA, Luo W, Kerr DJ: Effect of polyunsaturated fatty acids on the drug sensitivity of human tumor cell lines resistant to either cisplatin or doxorubicin. Br J Cancer 1993, 67, 728-733. (Pubitemid 23101550)
27. El-Mesery M, Al-Gavyar M, Salem H, Darweish M, El-Mowafy A: Chemopreventive and renal protective effects for docosahexaenoic acid (DHA): implications of CRP and lipid peroxides. Cell Div 2009, 4, 6.
28. de Lima TM, Amarante-Mendes GP, Curi R: Docosahexaenoic acid enhances the toxic effect of imatinib on Bcr-Abl expressing HL-60 cells. Toxicol In Vitro 2007, 21, 1678-1685.
29. Chen Y, Jungsuwadee P, Vore M, Butterfield A, Clair DKST: Collateral damage in cancer chemotherapy: oxidative stress in nontargeted tissues. Mol Interven 2007, 7, 147-156.